Over the last 7 days, the United States market has dropped 2.7%, but it has shown resilience with an 11% rise over the past year and earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive longer-term trends.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 235 stocks from our US High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Vertex

Simply Wall St Growth Rating: ★★★★★☆

Overview: Vertex, Inc. offers enterprise tax technology solutions for the retail trade, wholesale trade, and manufacturing industries both in the United States and internationally, with a market cap of approximately $5.39 billion.

Operations: Vertex, Inc. generates revenue primarily from its Software & Programming segment, which contributes approximately $666.78 million. The company focuses on providing tax technology solutions across retail trade, wholesale trade, and manufacturing sectors globally.

Vertex's trajectory in the high-growth tech sector is underscored by a robust forecast of 96.2% annual earnings growth and a projected revenue increase of 12.6% per year, outpacing the US market average of 8.5%. Despite current unprofitability, the firm is expected to shift into profitability within three years, reflecting its potential resilience and adaptability in a competitive landscape. Recent enhancements to their Vertex e-invoicing solution illustrate their commitment to innovation, addressing global complexities in tax regulation which could significantly streamline client operations worldwide. This strategic focus on scalable tech solutions not only meets increasing digital demands but also positions Vertex favorably for future industry requirements and growth.

• Unlock comprehensive insights into our analysis of Vertex stock in this health report.

• Understand Vertex's track record by examining our Past report.

Anavex Life Sciences

Simply Wall St Growth Rating: ★★★★★☆

Overview: Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company focused on developing therapeutics for central nervous system diseases in the United States, with a market cap of $742.61 million.

Operations: Anavex Life Sciences focuses on developing therapeutics for central nervous system diseases in the U.S. As a clinical stage biopharmaceutical company, it does not currently generate revenue from product sales.

Anavex Life Sciences, despite its current unprofitability with a net loss of $12.11 million in Q1 2025, shows promising clinical advancements. The company's oral blarcamesine for Alzheimer’s demonstrated a significant 36.3% slowdown in disease progression at 48 weeks during Phase IIb/III trials, underscoring its potential as an innovative treatment against neurodegeneration. With R&D expenses reflecting a strategic commitment to pioneering CNS disorder treatments, Anavex's focus on SIGMAR1 activation and autophagy restoration positions it uniquely within the biotech sector for future growth and medical impact.

• Click here to discover the nuances of Anavex Life Sciences with our detailed analytical health report.

• Explore historical data to track Anavex Life Sciences' performance over time in our Past section.

Sarepta Therapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in RNA-targeted therapeutics and gene therapies for rare diseases, with a market cap of $10.45 billion.

Operations: Sarepta Therapeutics focuses on the discovery, development, manufacturing, and delivery of therapies for rare diseases, generating revenue of $1.90 billion. The company operates within the biopharmaceutical sector with a specialization in RNA-targeted therapeutics and gene therapies.

Sarepta Therapeutics has demonstrated a robust turnaround, reporting a significant revenue increase to $1.9 billion in 2024 from $1.24 billion the previous year, reflecting a growth of over 53%. This surge is bolstered by its innovative gene therapy treatments such as ELEVIDYS for Duchenne muscular dystrophy, which alone is projected to garner between $2.9 billion and $3.1 billion in 2025. The firm's strategic R&D investments are paying off, evidenced by their latest successful Phase 3 clinical trial results and the securing of a substantial $600 million credit facility to fuel further advancements. With these developments, Sarepta is not only capitalizing on its niche in rare diseases but also setting the stage for sustained financial health and industry leadership.

• Click here and access our complete health analysis report to understand the dynamics of Sarepta Therapeutics.

• Review our historical performance report to gain insights into Sarepta Therapeutics''s past performance.

Turning Ideas Into Actions

• Unlock more gems! Our US High Growth Tech and AI Stocks screener has unearthed 232 more companies for you to explore.Click here to unveil our expertly curated list of 235 US High Growth Tech and AI Stocks.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGM:VERX NasdaqGS:AVXL and NasdaqGS:SRPT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com